Outstanding Contribution to Tumor Biology Award

Introduction: Welcome to the pinnacle of excellence in the realm of Tumor Biology—the 'Outstanding Contribution to Tumor Biology Award.' This prestigious accolade celebrates individuals who have made groundbreaking strides in advancing our understanding of tumor biology, fostering innovation, and making a lasting impact on the field.

Award Overview: This distinguished award is open to exceptional individuals who have demonstrated outstanding contributions to tumor biology through their research, publications, and community impact.

Eligibility:

  • No age limits
  • High academic qualifications
  • Notable publications in the field
  • Demonstrated significant contributions to tumor biology
  • Open to professionals and researchers worldwide

Evaluation Criteria: Candidates will be assessed based on the quality and impact of their contributions to tumor biology, research excellence, and community engagement.

Submission Guidelines:

  • Submit a comprehensive biography highlighting your achievements.
  • Include an abstract summarizing your contributions to tumor biology.
  • Attach supporting files showcasing the impact of your work.

Recognition: The recipient will receive widespread recognition through various platforms, highlighting their exceptional achievements in tumor biology.

Community Impact: Emphasis will be placed on the nominee's influence on the tumor biology community, fostering collaboration and knowledge sharing.

Innovator of the Year in Cancer Research Award

Innovator of the Year in Cancer Research Award

Introduction: Step into the future of cancer research with the Innovator of the Year in Cancer Research Award. This prestigious accolade recognizes visionaries who have redefined the landscape of oncology through groundbreaking research and innovation.

Award Eligibility: Open to global participants, this award has no age limits. Eligible candidates must hold a doctoral degree, showcase exceptional qualifications, and have a noteworthy publication history in cancer research.

Evaluation Criteria: Candidates will be evaluated based on the originality and impact of their research, as well as their overall contribution to advancing cancer knowledge. The selection process considers the quality and quantity of publications, recognizing those who have significantly influenced the field.

Submission Guidelines: Applicants are invited to submit a detailed biography, an abstract of their groundbreaking research, and supporting files that provide comprehensive insights. Detailed submission guidelines ensure all entries adhere to the specified format, facilitating a fair and thorough evaluation process.

Recognition and Community Impact: The award not only celebrates individual innovation but also acknowledges the broader impact of the recipient's work on the global cancer research community and its potential to shape the future of cancer treatment.

Excellence in Oncology Research Award

Excellence in Oncology Research Award

Introduction: Welcome to the forefront of groundbreaking oncology research! The Excellence in Oncology Research Award celebrates and honors outstanding contributions to the field, recognizing individuals who have demonstrated exceptional dedication and innovation in the pursuit of advancing our understanding and treatment of cancer.

Award Eligibility: This prestigious award is open to researchers, scientists, and medical professionals worldwide, irrespective of age. To qualify, candidates must possess a minimum qualification of a doctoral degree, showcase a robust publication record in esteemed journals, and demonstrate significant contributions to the field of oncology.

Evaluation Criteria: Candidates will be evaluated based on the novelty and impact of their research, the quality and quantity of publications, and their overall contributions to advancing oncology knowledge. Recognition of their work within the scientific community and the broader society will also be considered.

Submission Guidelines: Submissions should include a detailed biography, an abstract of the candidate's research, and supporting files that provide comprehensive insights into their work. Ensure all materials adhere to the specified format guidelines outlined in the submission instructions.

Recognition and Community Impact: The award not only recognizes individual excellence but also celebrates the broader impact of the recipient's work on the oncology community and society at large. Awardees will be acknowledged in high-profile events and publications, gaining visibility for their contributions.

Could Nanoparticles be the Future of Brain Cancer Treatment?

[ad_1]

oncology.pencis.com/”> A group of researchers at the University of Queensland (UQ), Australia, has recently developed an innovative Nanoparticle-based Conference-terms-conditions/”>Drug Delivery system that may help to overcome some of the challenges associated with Conference-terms-conditions/”>Drug Delivery for certain brain cancers.

oncology.pencis.com/”>
oncology.pencis.com/”>oncology.pencis.com/”>

oncology.pencis.com/”>Treating brain cancer effectively presents a series of challenges. For instance, certain Award-call-for-profile/”>Chemotherapy drugs are high in toxicity and have a limited lifespan in the Blood. Thus, developing new technologies for delivering such drugs is vital when it comes to ensuring patients get the most out of the therapeutic effects of the drugs.

oncology.pencis.com/”>Published in the Journal of Controlled Release, the team describes how they created a silica Nanoparticle that can carry temozolomide, a Award-call-for-profile/”>Chemotherapy drug typically used for treating malignant gliomas or glioblastomas.
oncology.pencis.com/”>Loaded Nanoparticles

oncology.pencis.com/”>Temozolomide was first approved for use in the EU and United States in 1999 and has proven to be an effective treatment for treating malignant tumors when exposed to the site of treatment consistently. However, achieving this successfully is also one of the main challenges that medical professionals face.

oncology.pencis.com/”>This Award-call-for-profile/”>Chemotherapy drug has limitations – it doesn’t stay in the Blood for very long, it can be pushed out of the brain, and it doesn’t have high penetration from Blood into the brain.

oncology.pencis.com/”>Dr. Taskeen Janjua, University of Queensland

oncology.pencis.com/”>By loading silica nanoparticles with temozolomide, the team was able to create a more efficient Conference-terms-conditions/”>Drug Delivery system.

oncology.pencis.com/”>To make the drug more effective, we developed an ultra-small, large pore Nanoparticle to help it move through the Blood-brain barrier and penetrate the tumor while also reducing unwanted patient side effects.

oncology.pencis.com/”>Dr. Taskeen Janjua, University of Queensland

oncology.pencis.com/”>Related Storiesoncology.pencis.com/”>cancer Cooking Lesson, A Basic Look At How Nanotechnology Can Be Used To Physically Destroy cancer Cells and Cure The Body of cancer
oncology.pencis.com/”>Nanoparticles Mediate Therapeutic Protein Delivery for Brain Injury Treatment
oncology.pencis.com/”>Nanoplatforms in Imaging-Guided Brain Tumor Treatment

oncology.pencis.com/”>In the trials, the team used multi-cellular 3D spheroids to mimic responses and interactions in brain tumor cells when exposed to the loaded silica nanoparticles. The team found that this system has the potential to penetrate the brain-Blood barrier and deliver temozolomide directly into the tumor.
oncology.pencis.com/”>Improving Brain cancer Treatment Strategies

oncology.pencis.com/”>Improving the ability to treat malignant glioblastomas is crucial as they are amongst the most aggressive and common forms of brain cancer with no known specific cause. In most cases, the chances are relatively high that patients will fall into remission due to the nature of these tumors and the limitations of current Conference-terms-conditions/”>Drug Delivery systems.

oncology.pencis.com/”>However, the team claims that this ground-breaking approach could not only improve the delivery of temozolomide but also could, in effect, improve the long-term potential of recovery as it may even prevent the cancer from returning.

oncology.pencis.com/”>The UQ team found that the Nanoparticle Conference-terms-conditions/”>Drug Delivery system also enhanced the cytotoxic efficacy of temozolomide against malignant glioblastoma cells.

oncology.pencis.com/”>Moreover, when treating their test animal models, the team discovered that the silica nanoparticles were able to reach the brain of the mice in just a few hours and had no negative impact on any other major organs in the body.

oncology.pencis.com/”>This innovative Conference-terms-conditions/”>Drug Delivery system has the potential to improve the effectiveness of brain cancer treatment and could lead to new and better treatments for this devastating disease.

oncology.pencis.com/”>Dr. Popat, Associate Professor, University of Queensland

oncology.pencis.com/”>Although brain cancers are not among the most common forms, they can be devastating as survival chances are lower than other forms of cancer, with the likelihood of surviving more than five years post-diagnosis being less than 23%.1

oncology.pencis.com/”>While the UQ team says more Research is required to further develop the silica-based Nanoparticle Conference-terms-conditions/”>Drug Delivery system, the results are promising.

oncology.pencis.com/”>This preclinical Research will accelerate future clinical development of a promising health technology and further the goal of improving outcomes for patients with brain cancer.

oncology.pencis.com/”>Dr. Popat, Associate Professor, University of Queensland
oncology.pencis.com/”>References and Further Reading

oncology.pencis.com/”>oncology.pencis.com/”>Nanoparticles deliver brain cancer treatment (2023) UQ News. Available at: https://www.uq.edu.au/News/article/2023/05/nanoparticles-deliver-brain-cancer-treatment

[ad_2]

Source link

Can You Help? – Chris’s Cancer Community

[ad_1]

I’m struggling to see the subject of cancer raised anywhere in mainstream news these days. However that doesn’t mean that the issues have disappeared. Quite the reverse of course. The situation for all of us is worsening by the day, but that doesn’t stop us from trying to improve things for our children and grandchildren. In my work I get to speak to so many wonderful people doing just that, and one of these is Lynette. She is looking for help to solve on of the biggest current inequalities in cancer within the UK

My name is Lynette and I am a trainee clinical psychologist from Canterbury Christ Church University, UK. I am conducting a research looking into the experiences of cancer and cancer care amongst young people from ethnically minoritised backgrounds.

cancer health disparities across different ethnic groups have been widely documented. In particular, low awareness of cancer symptoms, low participation in cancer screening programmes and delayed help seeking behaviours were more likely to be found in ethnically minoritised groups. Many patient experience studies have highlighted reports of poorer experiences of cancer care, quality of life and health outcomes amongst these ethnically minoritised populations. These aspects of cancer experience have been shown to be associated with cultural beliefs, misconceptions and stigma around cancer, for instance barriers to help-seeking, adjustment to diagnosis, illness disclosure and coping strategies.

Whilst there is a growing body of research shedding light on the lived experiences of ethnically minoritised adult cancer patients, only little research has been undertaken with the younger population. When presented with a life changing physical health condition during this developmental trajectory, adolescents and young adults are confronted with significant psychosocial challenges that interfere with their roles in relation to family relations, peer networks, education, employment and future aspirations. Research has shown that ethnically minoritised young people with cancer are more likely to have additional unmet needs, poorer quality of life and experiences of care. This population is faced with a ‘double disparity’, where they have to cope with cancer amongst challenges at a transitional age in tandem with barriers associated with identifying as ethnically marginalised. Yet there is little research looking into the challenges and unmet needs these young people face. I am interested in learning from young people’s personal experiences to help us understand better ways of supporting them in the service.

Looking for young people to help us improve cancer care. (UK only)

🚨Share your experience & earn a £10 voucher🚨

Are you:

Young person with experience of cancer

16-25 years old

identify as Black/Asian/Brown/People of Colour or Mixed Heritage?

Click below to sign up and find out more!

https://forms.gle/mQBvscXCZChL3PKt8

What it involves:

  • An online individual interview about your experience of cancer and care
  • About an hour
  • Participants will receive £10 voucher

☀️ You deserve better care, help us make a difference. ☀️

Please share wherever appropriate, as it is so important to improve our cancer care in the future, and Lynette would be extremely grateful!

[ad_2]

Source link

Latest advancements in cancer research and treatment

[ad_1]

oncology.pencis.com/”>

oncology.pencis.com/”>Advancements in cancer Research and treatment have revolutionized the way we understand and approach this complex disease.

oncology.pencis.com/”>With ongoing breakthroughs, scientists and healthcare professionals are constantly discovering new strategies and technologies to improve cancer outcomes.

oncology.pencis.com/”>In this article, we explore some of the latest advances in cancer Research and treatment that are offering hope to patients around the world:

oncology.pencis.com/”>Precision medicine: Personalized treatment approaches

oncology.pencis.com/”>cancer Research and treatment. (Image via Pexels)

oncology.pencis.com/”>Precision medicine is transforming cancer treatment by tailoring therapies to the unique genetic makeup of each individual’s cancer.

oncology.pencis.com/”>Genetic testing and molecular profiling enable oncologists to identify specific mutations and biomarkers, allowing for targeted therapies that attack cancer cells while minimizing harm to healthy cells. This approach has shown promising results, leading to improved treatment outcomes and reduced side effects.
oncology.pencis.com/”>Conference-registration-euro/”>immunotherapy: Harnessing power of immune system

oncology.pencis.com/”>Conference-registration-euro/”>immunotherapy has emerged as a groundbreaking treatment option that utilizes the body’s immune system to fight cancer.

oncology.pencis.com/”>It involves stimulating the immune system to recognize and destroy cancer cells. Checkpoint inhibitors, CAR-T Conference-sponsor/”>cell therapy and cancer vaccines are among the notable Conference-registration-euro/”>immunotherapy techniques that have shown remarkable success in treating various cancers and prolonging patient survival.
oncology.pencis.com/”>Liquid biopsies: Non-invasive cancer detection and monitoring

oncology.pencis.com/”>Liquid biopsies offer a non-invasive method for detecting and monitoring cancer. By analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) or other biomarkers present in Blood or other body fluids, liquid biopsies can provide valuable information about tumor characteristics, treatment response and potential resistance.

oncology.pencis.com/”>This approach is revolutionizing early cancer detection, monitoring treatment effectiveness and guiding personalized treatment decisions.
oncology.pencis.com/”>Targeted therapies: Disrupting cancer-specific pathways

oncology.pencis.com/”>Targeted therapies focus on specific molecules or pathways involved in cancer growth and survival.

oncology.pencis.com/”>By directly interfering with these cancer-specific targets, these therapies can effectively inhibit tumor growth and progression. Advancements in understanding tumor biology and development of targeted therapies have led to significant breakthroughs, particularly in cancers with specific mutations or genetic alterations.
oncology.pencis.com/”>Artificial intelligence and machine learning: Assisting diagnosis and treatment

oncology.pencis.com/”>Artificial intelligence and machine learning algorithms are being utilized to analyze vast amounts of patient data and assist in cancer diagnosis, prognosis and treatment planning.

oncology.pencis.com/”>These technologies can identify patterns and provide valuable insights for healthcare professionals, leading to more accurate and personalized treatment strategies. AI-powered imaging techniques also aid in early detection and precise tumor delineation.

oncology.pencis.com/”>The field of cancer Research and treatment is rapidly advancing, bringing new hope to patients and transforming the way we approach this complex disease and revolutionizing cancer care.

oncology.pencis.com/”>As these innovations continue to evolve, they hold the potential to improve patient outcomes, increase survival rates and eventually bring us closer to a world where cancer is no longer a formidable threat.

oncology.pencis.com/”>It’s important to note that while these advances have tremendous promise, they may not be applicable to all cancer types or individuals. Each patient’s treatment plan should be tailored to their specific diagnosis, characteristics and medical history.

oncology.pencis.com/”>Consulting with healthcare professionals and oncologists is crucial for personalized guidance and decision-making regarding the latest advancements in cancer Research and treatment.

[ad_2]

cancerResearch.html”>Source link

Receiving a Blood Transfusion During Cancer: What to Know and What to Expect

[ad_1]

Richard A. Larson, MD, is a professor of medicine in the Section of Hematology/oncology and director of the Hematologic Malignancies Clinical Research Program at the University of Chicago. He received his medical degree from the Stanford University School of Medicine and completed his postdoctoral training in Internal Medicine, Hematology, and Medical oncology at the University of Chicago. Dr. Larson is also a member of the 2023 cancer.Net Editorial Board. View Dr. Larson’s disclosures.

A Blood transfusion is a medical procedure to give Blood, or parts of the Blood, to someone who needs it. Some people may need a Blood transfusion if they have a medical condition, such as cancer, that affects how the body produces Blood cells. They may also require a Blood transfusion if they lose Blood after surgery or are experiencing other causes of bleeding.

Here, learn more about why you might receive a Blood transfusion during cancer, what to expect during a Blood transfusion, and what to know about the side effects you may experience after receiving a transfusion.

Why might someone with cancer need a Blood transfusion?

People with cancer may require a Blood transfusion for various reasons, depending on their specific condition and treatment. These reasons might include:

  1. Chemotherapy-induced Anemia. Chemotherapy can suppress the bone marrow’s ability to produce red Blood cells, leading to Anemia. Anemia is when you have a low level of red Blood cells in your body. Blood transfusions replenish the red Blood cell count and can relieve symptoms such as fatigue, weakness, and shortness of breath.

  2. Surgery-related Blood loss. cancer surgery can cause bleeding, and if the patient’s Blood volume drops too low, a Blood transfusion may be needed to restore it to a safe level.

  3. Bone marrow failure and Thrombocytopenia (low platelet count). Certain cancers, such as leukemia or myeloma, predominantly affect the bone marrow and interfere with the production of normal Blood cells. This is called “pancytopenia.” These diseases, as well as Chemotherapy, can interfere with the normal production and function of platelets, which help the Blood to clot. Platelet transfusions can help prevent or control bleeding episodes in these patients.

  4. Support during a bone marrow transplant. Before a bone marrow transplant, a person typically received high-dose Chemotherapy and/or radiation therapy, which can damage the bone marrow and reduce its ability to produce Blood cells. Then, during a bone marrow transplant, the diseased bone marrow is replaced by healthy stem cells from the donor. Blood transfusions may be necessary during this period to support the patient until the transplanted stem cells begin to function and produce new Blood cells.

What are the different types of Blood transfusions?

Blood is made up of different parts, or components. These components include the liquid plasma, red Blood cells, white Blood cells, and platelets. Transfusion of whole Blood is less common than transfusion of one of the Blood components. For most types of Blood transfusions, the Blood used comes from a donor. Special measures are used to ensure that Blood donation is safe for both recipients and donors.

The different types of Blood transfusion that your doctor may recommend during cancer and its treatment include:

Plasma transfusion

Plasma is the liquid part of Blood that carries the Blood cells. It contains proteins that help the Blood clot. It can be frozen and stored. A plasma transfusion can be given to people who have bleeding disorders, certain types of cancer, or liver disease. It may also be given after surgery if the person had considerable Blood loss.

Red Blood cell transfusion

Red Blood cells are made in the bone marrow and carry oxygen to the tissues in the body. Red Blood cells contain hemoglobin, which is a protein that carries oxygen and gives Blood its red color. Bleeding that is caused by trauma, surgery, or certain diseases may lead to a low red Blood cell count. If a person has a low red Blood cell count, a red Blood cell transfusion may be needed. A red Blood cell transfusion is usually given when a person’s red Blood cell count or hemoglobin level drops low enough to cause symptoms such as dizziness, fatigue, or shortness of breath.

Platelet transfusion

A low platelet count is called Thrombocytopenia. A platelet transfusion may be needed if the bone marrow cannot make enough platelets, which may occur during cancer or its treatment. There is a risk of spontaneous bleeding if a person’s platelet count falls too low. Platelets may be given in advance if there is an increased risk of bleeding from a surgical procedure. Sometimes, platelet transfusions are not needed despite a low platelet count if there are no signs of bleeding.

White Blood cell or granulocyte transfusion

White Blood cells help the body fight infection. Granulocyte transfusions are rarely given. They are usually reserved for people who have a very low white Blood cell count, called leukopenia or neutropenia, as well as for people who have a severe infection that doesn’t respond to antibiotics. Instead of transfusing white Blood cells, doctors commonly give injections of white Blood cell growth factors that stimulate the body to make its own white Blood cells.

Autologous Blood donation

In some cases, a person can serve as their own Blood donor. When someone donates their Blood for their own use, it is called an “autologous Blood donation” or “autotransfusion.” People may donate their own Blood before undergoing surgery in case they need a Blood transfusion during or after the procedure. Generally, Blood can be stored for up to 42 days.

How is the Blood prepared for transfusion?

Blood products that are used in transfusions are treated in special ways to make them safe and to prevent reactions in the recipient. Blood products may be treated with radiation before they are transfused. Radiation doesn’t affect red Blood cells or platelets, but it stops white Blood cells from functioning. Special Blood filters may also be used that help remove white Blood cells. This process is called “leukocyte reduction,” and it is used to help prevent a reaction in Blood transfusion recipients.

What should I expect during a Blood transfusion?

If your doctor has recommended that you receive a Blood transfusion, you will have a Blood test to find out your Blood type and Rhesus (Rh) factor. There are 4 Blood types: A, B, AB, or O. The Rh factor is an antigen that is found on the surface of some red Blood cells, making the cells “Rh-positive.” This information is important to know so that you receive Blood from a donor who matches your Blood type and Rh factor.

The Blood bank takes important precautions to prevent the recipient from having a reaction to the donated Blood. They cross-match the donor’s Blood to check that it matches and is compatible with the recipient’s Blood type. The health care team also carefully checks the donated Blood to make sure the right type of Blood is given to the right person. Before a transfusion, you may be given acetaminophen or antihistamines, such as diphenhydramine, to help prevent mild reactions.

During a Blood transfusion, an intravenous (IV) needle is inserted into a vein in your hand or arm. A bag of specially selected and matched Blood cells is hung on a pole, and the Blood flows from the bag through the IV and into your vein. Most of the time, people don’t feel any discomfort when the Blood goes in. However, the Blood is refrigerated, so it may feel a little cold.

During the transfusion, the nurse will monitor your temperature, Blood pressure, and heart rate. The nurse will also watch for any rash or signs of an allergic reaction. A red Blood cell transfusion usually takes between 2 and 3 hours. Platelet transfusions are shorter.

What are the possible side effects of a Blood transfusion?

A Blood transfusion is typically a very safe procedure, and the benefits of receiving a transfusion typically outweigh the possible risks. Adults or children who have received several Blood transfusions may have a higher risk of reacting to later Blood transfusions.

The health care team will watch you closely during a Blood transfusion to monitor for possible side effects. Although uncommon, some side effects that may occur during or after a Blood transfusion include:

  • Fever, chills, headache, or nausea. These symptoms can be caused by a reaction between the recipient’s immune system and the cells or proteins from the donated Blood. When this happens, the nurse may stop the transfusion and give a fever-reducing medicine. When the person’s temperature is back to normal, the transfusion can usually continue.

  • Allergic reaction. An allergic reaction can occur if the recipient’s immune system reacts to proteins in the donated Blood. These reactions may include hives or itching. In rare cases, a Blood transfusion can cause anaphylaxis, which is a severe and sometimes life-threatening allergic reaction. If an allergic reaction occurs, the transfusion is stopped and allergy medicines such as antihistamines and steroids are given. If the reaction is mild, the transfusion can start again. If the reaction is more serious, the transfusion is stopped.

  • Hemolytic reaction. This type of reaction is very rare but can occur when the donor’s and recipient’s Blood types do not match. During a hemolytic reaction, the recipient’s antibodies attack the transfused red Blood cells, causing them to break down, or hemolyze. The recipient develops fever, chills, or chest and lower back pain. This reaction can be mild or more severe. If severe, a hemolytic reaction can result in kidney damage or even death.

  • Transfusion-related acute lung injury (TRALI). This is a reaction of the recipient’s immune system to substances in the transfused Blood. TRALI damages lung tissue and causes fluid to accumulate in the lungs. TRALI may be immediate or delayed and causes difficulty breathing. Treatment for TRALI may include being given oxygen.

  • Circulatory overload. This occurs when the recipient’s circulatory system has too much Blood volume in it, which can cause difficulty breathing and heart failure. Circulatory overload is more likely to occur in older individuals and those with long-standing Anemia or heart problems. It is treated by stopping the transfusion, giving oxygen, and using a diuretic medicine to increase urination and lower the plasma volume.

  • Iron overload. Iron is present in red Blood cells and can build up after multiple Blood transfusions are given. Too much iron can damage the heart, liver, and other organs. Iron overload is usually treated with a chelating agent that binds to excess iron, causing it to be eliminated through the urine.

  • Infectious disease. The Blood you will receive during a transfusion is extremely safe because the Blood is tested for infectious organisms, and potential donors are carefully screened. However, there is a very small chance that an infectious disease may be transmitted through a Blood transfusion. Hepatitis virus and cytomegalovirus (CMV) are 2 viruses that can be transmitted through Blood transfusion. The human immunodeficiency virus (HIV), which causes acquired immune deficiency syndrome (AIDS), can also be transmitted through Blood.

Be sure to talk with your health care team if you have any questions or concerns about the Blood you will be receiving during your transfusion, how the Blood was tested and prepared, and what side effects might be possible after receiving a transfusion.

[ad_2]

cancer.net/blog/2023-10/receiving-Blood-transfusion-during-cancer-what-know-and-what-expect”>Source link

AI Algorithms Outperform Standard Models in Cancer Prediction

[ad_1]

June 08, 2023 – Research from the Radiological Society of North America (RSNA) indicates that artificial intelligence (AI) algorithms performed better than the Breast cancer Surveillance Consortium (BCSC) risk model in predicting the five-year risk of the disease.

Data from the Centers for Disease Control and Prevention (CDC) shows that 264,000 women and 2,400 men receive a breast cancer diagnosis annually.

Despite the various methods of predicting breast cancer, such as the BCSC risk model, their use can be taxing.
Dig DeeperDeep-Learning Tool Can Predict Lung cancer Risk Within Six Years
Genetic Mutation Data Indicates Ovarian cancer Risk
Predictive Analytics Model Helps Determine Colon cancer Risk

According to Vignesh A. Arasu, MD, PhD, a Research scientist and practicing radiologist at Kaiser Permanente Northern California, this is mainly because the information they require can be inaccessible or difficult to obtain. However, Arasu noted that technological advances and AI could make the process of evaluating mammograms more efficient.

To compare the abilities of AI to the BCSC model, Arasu conducted a retrospective study that involved negative screening 2D mammograms from Kaiser Permanente Northern California in 2016. From a pool of 324,009 women who were deemed eligible in 2016, mammograms from 13,628 were analyzed. The study also followed the 4,584 patients from the original patient population who received a cancer diagnosis within five years.

Researchers defined three time periods based on when the diagnosis occurred: interval cancer risk, describing diagnoses between zero and one year; future cancer risk, describing diagnoses from between one and five years; and all cancer risk, encompassing the entirety of the five-year period.

Researchers used a total of five AI algorithms for the study, two of which were academic algorithms and three of which were commercially available. After comparing their performance to the abilities of the BCSC risk model, researchers found that the AI algorithms performed better than the standard risk model.

“All five AI algorithms performed better than the BCSC risk model for predicting breast cancer risk at 0 to 5 years,” said Arasu in a press release. “This strong predictive performance over the five-year period suggests AI is identifying both missed cancers and breast tissue features that help predict future cancer development. Something in mammograms allows us to track breast cancer risk. This is the ‘black box’ of AI.”

Beyond this, the AI algorithms presented several other benefits. Researchers also noted that certain AI algorithms performed well in predicting those at risk of interval cancer. This is critical, as this generally requires follow-up mammogram readings.

Also, even AI algorithms that did not have a long training duration performed well.

“We’re looking for an accurate, efficient and scalable means of understanding a women’s breast cancer risk,” said Arasu. “Mammography-based AI risk models provide practical advantages over traditional clinical risk models because they use a single data source: the mammogram itself.”

AI is playing an increasingly significant role in cancer prediction and detection, serving as the foundation of many Research efforts.

A large grant from the National cancer Institute in November 2022 led researchers from the University of California Davis to fuel AI projects to enhance breast cancer screening and risk prediction. Through these efforts, researchers aimed to reduce health disparities.

Often, certain types of regular screening can lead to false positive results. The grant, however, will support researchers as they test whether new AI and imaging features can improve risk prediction models.

Tagged Artificial Intelligence  Predictive Analytics  Risk Assessment

[ad_2]

Source link

2021 Year in Review | CancerCare

[ad_1]

It’s hard to believe that 2021 is nearly over! Throughout the year, cancerCare has continued to support the growing and changing needs of those impacted by a cancer diagnosis. We are excited to share a selection highlights and achievements:

In January, we published the updated 2021 edition of our Helping Hand guide. This guide offers information for organizations offering practical and financial support and the 2022 edition will be published soon. In the meantime, search our Online Helping Hand for resources.

Our Pen Pal Program helps older adults reduce feelings of isolation. To mark National Volunteer Month, we interviewed oncology social worker Danielle Saff, MSW, LMSW, and our program partner, Caring for Seniors founder Nina Rawal.

alt textOur first-ever virtual gala raised over $800,000 to support our free programs and services! The event included unforgettable auction items and a performance from Tony Award-winner Laura Benanti.

We partnered with Gryt Health to share the wisdom of one of our social workers, Charlotte Ference, MSW, LMSW, about mental health and coping with cancer.

Our dedicated team planned a full virtual weekend of activities for families coping with the loss of a loved one. cancerCare’s first all-virtual Healing Hearts Family Bereavement Camp was a resounding success!

We took a look back at the first year of our free telephone case management service, helping clients overcome barriers to care.

alt textIn August, we launched Magnolia Purpose in Planning in partnership with Triage cancer. Magnolia Purpose in Planning connects people affected by cancer to practical and legal resources they need to plan for the future.

To celebrate cancer Out Loud’s season 4 launch, we looked back at the program’s beginnings and its future in a two-part interview with staff.

Our CEO, Patricia J. Goldsmith, was named to the Forbes 50 Over 50 Vision List, alongside figures like Geena Davis, Eileen Fisher and Wally Funk.

The cancerCare Young Professionals Committee’s Scholarship Program re-opened for young adults who have lost a parent to cancer. To commemorate the passing of former YPC board member and client Seynabou Ba, we also created The Seynabou Ba Fund thanks to an anonymous donor.

alt textOne hundred and forty children and teens received backpacks and school supplies as part of our annual Back-to-School Program.

In October, for Breast cancer Awareness Month, we partnered with Awe Inspired to share information on body image and post-treatment survivorship.

For Lung cancer Awareness Month, Long Island Social Services Director Winfield Boerckel, MSW, MBA, LCSW-R, shared his insights and observations after a 25-year career in social work and lung cancer advocacy. Win will be retiring at the end of this year, and we salute him for a quarter century of serving the lung community!

cancerCare is able to serve thousands of clients across the nation each year thanks to the generosity of our supporters. We are grateful each day for the impact we are able to have on those coping with a cancer diagnosis. If you would like to support our free programs and services, please consider making a donation to cancerCare.



[ad_2]

Source link